The company completed the sale of its Critical Care product group to Becton, Dickinson and Company for $4.2 billion. This strategic move enables the company to focus on expanding opportunities within TAVR, TMTT, and Surgical patients, as well as new investments in interventional heart failure technologies.

The company completed the acquisition of Endotronix, Inc., a leader in heart failure management solutions, as well as the acquisition of JC Medical, Inc., an early-stage company developing a TAVR technology for patients with aortic regurgitation. These acquisitions signal a commitment to innovation and expansion into new therapeutic areas.

The company invested 19% of its net sales in research and development in 2024. This highlights a commitment to developing new technologies and innovations to treat valvular and non-valvular structural heart disease.

Management successfully executed the sale of the Critical Care product group and is now focused on integrating recent acquisitions. This demonstrates an ability to manage complex transactions and strategic shifts.

The company received FDA approval and launched the EVOQUE tricuspid valve replacement system in the United States. They also announced positive results from the EARLY TAVR and TRISCEND II trials, demonstrating progress in clinical research and regulatory approvals.

Management is focused on generating robust clinical, economic, and quality-of-life evidence to support the adoption of innovative new medical therapies. This demonstrates a commitment to providing value to patients, clinicians, and payers.

The company acknowledges the ongoing threat of cybersecurity attacks and the potential for disruptions to its information technology systems and products. This could lead to decreased sales, liability claims, regulatory penalties, and other adverse effects.

The company relies on third parties for the design, manufacture, and sterilization of its products, and any failure by or loss of a vendor could result in delays and increased costs.

The company is subject to increasingly complex and changing legal and regulatory requirements that govern the collection, use, storage, security, transfer, disclosure, and other processing of personal data in the United States and in other countries.

The company acknowledges that it operates in highly competitive markets and competes with technologies of many types and companies of all sizes on the basis of cost-effectiveness, technological innovations, product performance, brand name recognition, breadth of product offerings, real or perceived product advantages, pricing and availability and rate of reimbursement.

The company's continued growth and success depend on its ability to innovate and develop new and differentiated products in a timely manner and effectively market these products.

The success of many of the company's products depends upon certain key physicians, research institutions, and hospital systems.

The manufacture and sterilization of many of the company's products is highly complex due in part to rigorous regulatory requirements. Quality is extremely important due to the serious and costly consequences of a product failure.

The medical technology industry has also experienced some consolidation, partly in order to offer a broader range of products to large purchasers. As a result, transactions with customers are larger, more complex, and tend to involve more long-term contracts than in the past.

The company experiences from time to time, and may continue to experience, supply interruptions due to a variety of factors, including General economic conditions that could adversely affect the financial viability of our vendors.

The company's continued growth and success depend on its ability to innovate and develop new and differentiated products in a timely manner and effectively market these products.

Patents, trademarks, and other proprietary rights are important to the success of the company's business. The company also relies upon trade secrets, know-how, continuing innovations, licensing opportunities, and non-disclosure agreements to develop and maintain our competitive position.

In many of the other foreign countries in which the company markets its products, it may be subject to regulations affecting, among other things, product standards and specifications.

In August 2024, the Board of Directors approved a stock repurchase program providing for up to $1.5 billion of repurchases of the company's common stock.

In August 2024, the company entered into a $500.0 million accelerated share repurchase agreement and received, on September 5, 2024, an initial delivery of 5.8 million shares of the company's common stock, representing approximately 80 percent of the total contract value.

The company is subject to income taxes in the United States as well as other jurisdictions.

The company is committed to providing a safe and healthy workplace and complying with all relevant regulations and medical technology industry standards.

The primary goals of the company's talent management strategy are to attract, develop and retain a motivated, professional workforce and to strive for alignment on our patient-focused innovation strategy.

The company's operations are subject to environmental, health, and safety laws, and regulations concerning, among other things, the generation, handling, transportation, and disposal of hazardous substances or wastes, the cleanup of hazardous substance releases, and emissions or discharges into the air or water.

The medical technology industry has also experienced some consolidation, partly in order to offer a broader range of products to large purchasers.

As a result of these changes, the marketplace has placed increased emphasis on the delivery of more cost-effective medical therapies.

The company's extensive global operations and business activity as well as the fact that many of our manufacturing facilities and suppliers are outside of the United States expose us to certain financial, economic, political, and other risks.